RESUMO
BACKGROUND: Although the randomized mycophenolate mofetil- (MMF) azathioprine (AZA) trial is likely applicable to cardiac transplantation in general, it was limited to select and usually larger cardiac transplant centers and suffered from substantial cross-over and failure of many patients to receive assigned treatment drug. METHODS: The Joint ISHLT/UNOS Thoracic Registry was analyzed for the effects of MMF versus AZA in patients 1) on a cyclosporine- (CsA) based immunosuppression protocol; 2) having survived long enough to be discharged from the transplant hospitalization. RESULTS: A total of 5599 patients (4942 CsA/AZA and 657 CsA/MMF) were included with no significant differences between the MMF and AZA groups in baseline characteristics with the exception of recipient age (50 vs. 47 years), donor age (29 vs. 28 years), ischemic time (3.0 vs. 2.9 hr), and pretransplant medical condition (more AZA patients in ICU, more MMF patients on VAD). Actuarial survival was greater in the MMF group compared to the AZA group in patients surviving the initial transplant hospitalization (1 year 96 vs. 93%, 3 years 91 vs. 86%, P=0.0012). This difference was confirmed in the logistic regression analysis of 3-year mortality showing a relative risk of 0.62 (P=0.011). CONCLUSIONS: These data provide independent support for the broad applicability of the positive results from the randomized MMF-AZA clinical trial in a substantially larger patient population and confirm improved survival in patients using mycophenolate mofetil compared to azathioprine late after cardiac transplantation.
Assuntos
Azatioprina/uso terapêutico , Transplante de Coração/mortalidade , Imunossupressores/uso terapêutico , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Adulto , Idoso , Feminino , Hospitalização , Humanos , Masculino , Pessoa de Meia-Idade , Sistema de RegistrosRESUMO
BACKGROUND: The appropriate age to perform bilateral, sequential lung transplants (BSLT) in patients with chronic obstructive pulmonary disease (COPD) remains controversial. Although single lung transplant (SLT) offers an advantage in terms of organ availability, the long-term survival may not warrant this strategy in all age groups. METHODS: We analyzed 2,260 lung transplant recipients (1835 SLT, 425 BSLT) with COPD recorded in the International Society for Heart and Lung Transplantation/United Network for Organ Sharing thoracic registry between January 1991 and December 1997. To assess mortality, we performed univariate (Kaplan-Meier method and the chi-square statistic) and multivariate analyses (proportional hazards method). Because of incomplete morbidity data in the international registry, only data from U.S. centers (n = 1778, 1467 SLT, 311 BSLT) were used in the morbidity analysis. RESULTS: Survival rates (%) computed using the Kaplan-Meier method at 30 days, 1 year, and 5 years for the patients aged < 50 years were 93.6, 80.2, and 43.6, respectively, for the SLT patients, and 94.9, 84.7, and 68.2, respectively, for the BSLT patients. For patients aged 50 to 60 years, survival rates (%) were 93.5, 79.4, and 39.8 for the SLT patients compared with 93.0, 79.7, and 60.5 for the BSLT patients. For those aged > 60 years, SLT survival (%) was 93.0, 72.9, and 36.4, compared with 77.8 and 66.0 for the BSLT group (a 5-year rate could not be completed in this group). The multivariate model showed a higher risk ratio for mortality in patients aged 40 to 57 years who received SLT vs BSLT. Recipient age and procedure type did not appear to affect the development of rejection, bronchiolitis obliterans, bronchial stricture, or lung infection. CONCLUSIONS: Single lung transplant may offer acceptable early survival for patients with end-stage respiratory failure. However, long-term survival data favors BSLT in recipients until approximately age 60 years. These data suggest that a BSLT approach offers a significant survival advantage to recipients younger than 60 years of age.
Assuntos
Enfisema/mortalidade , Enfisema/cirurgia , Transplante de Pulmão/mortalidade , Adulto , Fatores Etários , Idoso , Enfisema/epidemiologia , Determinação de Ponto Final , Feminino , Seguimentos , Humanos , Pneumopatias Obstrutivas/epidemiologia , Pneumopatias Obstrutivas/mortalidade , Pneumopatias Obstrutivas/cirurgia , Masculino , Pessoa de Meia-Idade , Morbidade , Análise Multivariada , Razão de Chances , Complicações Pós-Operatórias/epidemiologia , Valor Preditivo dos Testes , Análise de Sobrevida , Tempo , Fatores de Tempo , Resultado do Tratamento , Estados Unidos/epidemiologiaAssuntos
Transplante de Coração/mortalidade , Transplante de Pulmão/mortalidade , Sistema de Registros/estatística & dados numéricos , Sociedades Médicas , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Taxa de SobrevidaAssuntos
Transplante de Coração-Pulmão/estatística & dados numéricos , Cooperação Internacional , Pediatria/estatística & dados numéricos , Sistema de Registros , Sociedades Médicas/estatística & dados numéricos , Criança , Cardiopatias Congênitas/cirurgia , Transplante de Coração-Pulmão/tendências , Humanos , Pulmão/anormalidades , Pneumopatias/congênito , Pneumopatias/cirurgia , Pediatria/métodos , Pediatria/tendências , PrognósticoRESUMO
BACKGROUND: Pressure to expand the donor pool has required the use of lungs from older donors or from more-distant procurement areas. The long-term consequences of this policy have not yet been fully addressed. The effect of donor age and donor ischemic time on intermediate survival and important secondary end points after lung transplantation was therefore examined. METHODS: A cohort of 1,800 lung transplant recipients with complete 2-year follow-up, operated on in the United States between April 1, 1993, and March 31, 1996, was studied to assess survival. For analysis of secondary end points, the cohort was limited to 1,450 patients. RESULTS: Donor age when analyzed independently did not significantly affect intermediate survival (p = 0.4). Secondary end points were also not affected by age, with the exception of the incidence of hospitalization for rejection in the univariate analysis (p = 0.02) and in the multivariate analysis (p = 0.04). Moreover, there was not a significant impact of donor age or ischemic time independently on survival in the multivariate analysis. Similarly, when the interaction between ischemic time and donor age was examined in all of the multivariate models, none of the secondary end points were found to be significantly influenced. However, the combined interaction between donor age and ischemia time demonstrated a significantly worse survival at 2 years (p = 0.02) with donor age of > 50 years and donor ischemic time > 7 h. CONCLUSIONS: Donor age and donor ischemic time did not independently influence survival or important secondary end points after lung transplantation. However, intermediate-term survival was affected by the use of older donors when combined with a prolonged ischemic time. The impact of this combination should be considered when attempting to expand the donor pool.
Assuntos
Sobrevivência de Enxerto , Transplante de Pulmão/métodos , Preservação de Órgãos , Doadores de Tecidos , Análise Atuarial , Adulto , Fatores Etários , Análise de Variância , Distribuição de Qui-Quadrado , Estudos de Coortes , Feminino , Seguimentos , Rejeição de Enxerto/etiologia , Hospitalização , Humanos , Incidência , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Taxa de Sobrevida , Fatores de Tempo , Obtenção de Tecidos e ÓrgãosAssuntos
Transplante de Coração/estatística & dados numéricos , Transplante de Pulmão/estatística & dados numéricos , Sistema de Registros , Análise Atuarial , Adolescente , Adulto , Idoso , Canadá , Criança , Pré-Escolar , Europa (Continente) , Feminino , Cardiopatias/cirurgia , Transplante de Coração/mortalidade , Transplante de Coração-Pulmão/estatística & dados numéricos , Humanos , Lactente , Pneumopatias/cirurgia , Transplante de Pulmão/mortalidade , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Artéria Pulmonar/fisiopatologia , Fatores de Risco , Fatores de Tempo , Estados Unidos , Resistência VascularRESUMO
BACKGROUND: Hepatitis B surface antigenemia (HBsAg) has been considered at least a relative contraindication for heart transplantation, yet patients have undergone liver transplantation for hepatitis B-induced chronic liver disease, albeit with poorer results than for other liver diseases. The impact of asymptomatic hepatitis B infection on heart transplant outcome is not known. METHODS: To examine this question, we queried the Joint International Society for Heart and Lung Transplantation/United Network of Organ Sharing Thoracic Registry for all patients undergoing heart transplantation who had been identified as positive for HBsAg before transplantation. We then sent a 4-question data instrument to the centers responsible for the identified patients. Seventy-eight patients were identified. Of the 78 data forms sent, 53 forms were returned with the requested data. Of the 53 data forms returned, the centers incorrectly identified 23 patients as positive for HBsAg, resulting in 30 patients who were confirmed as HBsAg positive and who served as the final cohort for this analysis. RESULTS: The cohort included 24 males and 6 females, with a mean age of 46 +/- 16 years (range 0 to 68 years). Eleven patients had coronary artery disease, 14 had dilated cardiomyopathy, and 5 patients had a variety of other cardiac diseases. Of those tested at most recent follow-up, 20 of 25 patients continued to be positive for HBsAg, whereas 7 of 21 patients studied had converted and were hepatitis B serum antibody-positive. Approximately 37% of the patients had evidence of active hepatic inflammation or cirrhosis. We found a statistically significant correlation between positivity for hepatitis C antibodies and clinical liver disease (p = 0.0105). No difference in survival could be demonstrated between the study cohort and a reference heart transplant cohort, yet 5 of the 9 deaths were considered to be related to hepatitis B. CONCLUSIONS: These data demonstrate that clinical liver disease is common post-transplantation in HBsAg+ patients who presumably have no overt liver disease at the time of transplantation. Despite the inability to show a survival difference in this cohort, the fact that the majority of deaths were related to hepatitis B should suggest caution in accepting HBsAg+ patients for cardiac transplantation.
Assuntos
Transplante de Coração , Antígenos de Superfície da Hepatite B/sangue , Hepatite B/complicações , Transplante de Pulmão , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Transplante de Coração/mortalidade , Hepatite B/mortalidade , Humanos , Lactente , Agências Internacionais , Transplante de Pulmão/mortalidade , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Inquéritos e Questionários , Taxa de Sobrevida , Obtenção de Tecidos e Órgãos/organização & administração , Resultado do TratamentoRESUMO
BACKGROUND: It is well established that repeat heart transplantation has a significantly worse outcome when compared with primary (first time) transplantation. Defining the risk factors for mortality within this group has been difficult due to small numbers of patients at individual centers. METHODS: All cardiac retransplants performed in the United States and registered in the Joint International Society for Heart and Lung Transplantation (ISHLT)/United Network for Organ Sharing (UNOS) Thoracic Registry were analyzed for demographics, morbidity posttransplantation, immunosuppression, and risk factors for mortality. RESULTS: The study cohort included 514 patients of which 81% were male with a mean age of 47+/-12 years. Time from primary transplant to retransplantation ranged from 1 day to 15.5 years and more than 50% of the patients underwent retransplantation for chronic rejection. More than 60% of patients were in the intensive care unit at the time of retransplantation and more than 40% of the patients were reported to be on some form of life support (ventricular assist device, ventilator, and/or inotropic therapy). Survival for the entire retransplant cohort was 65, 59, and 55% for 1, 2, and 3 years, respectively, but was substantially lower when the intertransplant interval was short. Conversely, when the interval between primary and retransplantation was more than 2 years, 1 year survival postretransplantation approached that of primary transplantation. Additional independent risk factors for mortality for the retransplant cohort included overall cardiac transplant center volume, the use of a ventricular assist device or ventilator, the patient being in the intensive care unit, and recipient age. The four most common causes of death were infection, primary/nonspecific graft failure, chronic rejection (allograft vasculopathy), and acute rejection. CONCLUSIONS: The data confirm that repeat heart transplantation is a higher risk procedure than primary transplantation, especially early after the primary heart transplant.
Assuntos
Transplante de Coração/estatística & dados numéricos , Complicações Pós-Operatórias/epidemiologia , Sistema de Registros , Reoperação/estatística & dados numéricos , Obtenção de Tecidos e Órgãos/organização & administração , Adulto , Feminino , Seguimentos , Rejeição de Enxerto/cirurgia , Sobrevivência de Enxerto , Transplante de Coração/mortalidade , Transplante de Coração/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Readmissão do Paciente , Reoperação/mortalidade , Taxa de Sobrevida , Fatores de Tempo , Estados UnidosRESUMO
Cyclosporine has potent antiproliferative properties, some of which may be via the induction of the cyclin inhibitor p21. In this study, we describe the effects of in vitro and in vivo transfection of p21 in lymphoid and nonlymphoid cells. For in vitro studies, p21 sense plasmid DNA was transfected in A-549 cells (lung adenocarcinoma cell line) and Jurkat cells (human lymphoid cell line). This in vitro transfection of p21 resulted in the inhibition of spontaneous and mitogen-induced cellular proliferation ([3H]thymidine uptake) and also augmented the antiproliferative effects of cyclosporine. In vivo transfection of p21 was accomplished in mice via the i.m. injection of p21 sense plasmid DNA complexed with cationic lipids. As was the case in the cell lines, p21 mRNA was augmented in heart, lung, liver, and spleen 7 days after i.m. injection of p21 sense plasmid DNA. The mitogen (anti-CD3)-induced proliferation of splenocytes from p21-overexpressing mice was significantly decreased, and again this effect was augmented by cotreatment with cyclosporine. These novel findings demonstrate the potential of targeting the cell cycle directly to inhibit alloimmune activation in organ transplantation. This may serve as an alternate strategy to induce immunosuppression, perhaps with less toxicity than that which is seen with conventional immunosuppressive agents.
Assuntos
Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/genética , Ciclinas/administração & dosagem , Ciclinas/genética , Ciclosporina/farmacologia , Imunossupressores/farmacologia , Ativação Linfocitária/efeitos dos fármacos , Transfecção/imunologia , Animais , Inibidor de Quinase Dependente de Ciclina p21 , Ciclinas/biossíntese , Ciclinas/fisiologia , Regulação da Expressão Gênica/imunologia , Inibidores do Crescimento/farmacologia , Humanos , Injeções Intramusculares , Células Jurkat , Rim/metabolismo , Fígado/metabolismo , Ativação Linfocitária/genética , Ativação Linfocitária/imunologia , Camundongos , Miocárdio/metabolismo , Especificidade de Órgãos/genética , Especificidade de Órgãos/imunologia , Plasmídeos/administração & dosagem , Plasmídeos/síntese química , Plasmídeos/imunologia , Baço/citologia , Baço/imunologia , Baço/metabolismo , Células Tumorais CultivadasRESUMO
BACKGROUND: The impact of acute rejection, immunosuppression, and infection, specifically cytomegalovirus infection, on the development of chronic rejection in the cardiac allograft, has been the subject of a large number of investigations. One of the difficulties in finding associations has been the marked immunologic heterogeneity of the patient population coupled with the lack of the ability to HLA match. Furthermore, the ideal animal model, which duplicates as well as controls for this immunologic heterogeneity, is lacking. METHODS: To try to simulate differences in HLA matching, immunosuppression regiments and cytomegalovirus infection, heterotopic heart transplantation was performed in two separate, complete MHC mismatch, rat strain combinations (WF-LEW, BN-LEW) requiring chronic immunosuppression and employing four separate immunosuppression/infection protocols. Animals were followed for 6 months, killed, and rejection and vascular changes were scored blinded to the group. RESULTS: The mean vascular and acute rejection scores were not significantly different between treatment regiments for either specific strain combination. There was a trend for the subtherapeutic groups to have higher vascular scores. Overall, there were no significant differences in vascular scores between the WF-LEW and BN-LEW groups (1.25+/-0.18 vs. 1.13+/-0.20, P=NS). Similar numbers of WF-LEW and BN-LEW exhibited cellular infiltration and necrosis of the allograft, but the intensity of the response (rejection score) was more severe in the WF-LEW combination (4.54+/-0.22 vs. 3.92+/-0.21, P=0.052) when limiting the analysis to those with myocyte necrosis. There was no significant correlation between acute rejection and vascular lesion severity in the WF-LEW combination (r=0.22, P=NS) but a high correlation between these parameters in the BN-LEW combination (r=0.74, P<0.0001). CONCLUSIONS: These data suggest that, although acute rejection and chronic rejection are related, MHC matching may influence their interdependence. These data also may explain why the clinical association between acute and chronic rejection is difficult to demonstrate.
Assuntos
Rejeição de Enxerto/imunologia , Transplante de Coração/imunologia , Teste de Histocompatibilidade , Complexo Principal de Histocompatibilidade , Doença Aguda , Animais , Doença Crônica , Ciclosporina/uso terapêutico , Citomegalovirus/isolamento & purificação , Infecções por Citomegalovirus/complicações , Rejeição de Enxerto/patologia , Rejeição de Enxerto/prevenção & controle , Transplante de Coração/patologia , Transplante de Coração/fisiologia , Complicações Pós-Operatórias , Ratos , Ratos Endogâmicos BN , Ratos Endogâmicos Lew , Ratos Endogâmicos WF , Transplante Homólogo , Ensaio de Placa ViralRESUMO
OBJECTIVE: Peripartum cardiomyopathy (PPCM) is a rare life-threatening cardiomyopathy of unknown cause that occurs in the peripartum period in previously healthy women. In April 1997, the National Heart, Lung, and Blood Institute (NHLBI) and the Office of Rare Diseases of the National Institutes of Health (NIH) convened a Workshop on Peripartum Cardiomyopathy to foster a systematic review of information and to develop recommendations for research and education. PARTICIPANTS: Fourteen workshop participants were selected by NHLBI staff and represented cardiovascular medicine, obstetrics, immunology, and pathology. A representative subgroup of 8 participants and NHLBI staff formed the writing group for this article and updated the literature on which the conclusions were based. The workshop was an open meeting, consistent with NIH policy. EVIDENCE: Data presented at the workshop were augmented by a MEDLINE search for English-language articles published from 1966 to July 1999, using the terms peripartum cardiomyopathy, cardiomyopathy, and pregnancy. Articles on the epidemiology, pathogenesis, pathophysiology, diagnosis, treatment, and prognosis of PPCM were included. RECOMMENDATION PROCESS: After discussion of data presented, workshop participants agreed on a standardized definition of PPCM, a general clinical approach, and the need for a registry to provide an infrastructure for future research. CONCLUSIONS: Peripartum cardiomyopathy is a rare lethal disease about which little is known. Diagnosis is confined to a narrow period and requires echocardiographic evidence of left ventricular systolic dysfunction. Symptomatic patients should receive standard therapy for heart failure, managed by a multidisciplinary team. If subsequent pregnancies occur, they should be managed in collaboration with a high-risk perinatal center. Systematic data collection is required to answer important questions about incidence, treatment, and prognosis.
Assuntos
Cardiomiopatias , Complicações Cardiovasculares na Gravidez , Cardiomiopatias/diagnóstico , Cardiomiopatias/epidemiologia , Cardiomiopatias/etiologia , Cardiomiopatias/terapia , Fármacos Cardiovasculares , Congressos como Assunto , Ecocardiografia , Feminino , Humanos , Incidência , National Institutes of Health (U.S.) , Guias de Prática Clínica como Assunto , Gravidez , Complicações Cardiovasculares na Gravidez/diagnóstico , Complicações Cardiovasculares na Gravidez/epidemiologia , Complicações Cardiovasculares na Gravidez/etiologia , Complicações Cardiovasculares na Gravidez/terapia , Terceiro Trimestre da Gravidez , Gravidez de Alto Risco , Prognóstico , Transtornos Puerperais , Fatores de Risco , Estados Unidos , Disfunção Ventricular EsquerdaRESUMO
Based on data reported to the UNOS/ISHLT International Registry for Thoracic Organ Transplantation, we showed that: 1. The number of heart transplant operations performed in the United States has decreased by 164 procedures between 1998 (2,346) and 1999 (2,182). The number of lung transplants increased by 13 in 1999 to 877. 2. The most frequently reported indication for heart transplantation in the US is coronary artery disease (44.8%). For other thoracic transplants, the most frequently reported indications include cystic fibrosis (35.5%) for double lung, emphysema/COPD (49.7%) for single lung and congenital heart disease (46.6%) for heart-lung. The most frequently reported diagnoses for thoracic transplantation outside the US include cardiomyopathy (43.8%) for heart, cystic fibrosis (33.4%) for double-lung, emphysema/COPD (26.6%) for single-lung and primary pulmonary hypertension (24.8%) for heart-lung transplants. 3. US heart transplant recipients are predominately male (76.7%), between 50 and 64 years of age (51.3%) and white (81.4%). US lung transplant recipients are also predominately between 50 and 64 years of age (44.7%) and white (89.9%), but unlike heart recipients are more likely to be female (51.2%). No meaningful variance from the US recipient demographic profile is noted for the non-US recipients during the same time period. 4. Pediatric recipients (< 18 years of age) received 10.9% of the reported heart transplants and 6.2% of reported lung transplants. 5. One-year survival for thoracic transplants performed in the US is 82.4% for heart, 74.1% for lung and 62.0% for heart-lung. Five-year survival for US thoracic transplants is 66.8% for heart and 43.2% for lung. 6. Long-term patient survival rates are: 22.5% at 17 years for heart, 20.8% at 10 years for lung and 24.3% at 13 years for heart-lung recipients. 7. The most important risk factor for mortality of US heart recipients at one month, one year and conditionally at 5 years after transplantation was receipt of a previous heart transplant. Significant short-term risk factors include donor age, recipient age and ischemic time. Substantial long-term risk factors include older donor age, recipient age, recipient race and diagnosis. 8. The factors having the most significant impact on lung mortality at all time points are related to either the patient's medical condition (e.g., in the ICU prior to transplant, requiring mechanical ventilation) or diagnosis. 9. Mechanical ventilation, recipient race and recipient age have the largest impact on heart-lung mortality. 10. For heart and lung recipients, the major cause of hospitalization during the first year after transplantation is infection alone.
Assuntos
Transplante de Órgãos , Sistema de Registros , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Transplante de Coração/efeitos adversos , Transplante de Coração/mortalidade , Transplante de Coração/estatística & dados numéricos , Transplante de Coração-Pulmão/mortalidade , Transplante de Coração-Pulmão/estatística & dados numéricos , Humanos , Terapia de Imunossupressão , Lactente , Agências Internacionais , Transplante de Pulmão/efeitos adversos , Transplante de Pulmão/mortalidade , Transplante de Pulmão/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Morbidade , Transplante de Órgãos/estatística & dados numéricos , Taxa de Sobrevida , Doadores de Tecidos , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Cytomegalovirus (CMV) has been associated with the development of chronic allograft rejection. Attempts to delineate pathogenetic mechanisms for this association have characteristically used well-established laboratory strains for in vitro investigation and rodent strains for in vivo studies. There is substantial genetic heterogeneity not only among different laboratory strains, but also between laboratory strains and clinical isolates, and genetic differences between human and animal strains are profound. Given these genetic differences, one would anticipate differences in biological activity between strains. METHODS: Vascular endothelial cells were infected with two laboratory strains of CMV (Towne and AD-169) as well as two individual clinical CMV isolates, after genetic typing with six segments of the genome (including early and late genes). mRNA expression coding for a panel of mesenchymal growth factors was studied using quantitative reverse transcription, polymerase chain reaction. Major histocompatibility complex (MHC) expression was investigated using flow cytometry. RESULTS: There was substantial genetic variability between clinical and laboratory isolates. There did not appear to be differences in overall infectivity by the different strains as determined by expression of immediate-early antigen at 24 hours (5-10% of endothelial cells positive for immediate-early. Two growth factors, platelet-derived growth factor-A and basic fibroblast growth factor were augmented by one of the two clinical strains of CMV (Clin 2) (P=0.0091 and P=0.0018, respectively). Transforming growth factor -alpha and insulin-like growth factor expression were significantly reduced by both clinical strains and AD-169. Two other growth factors, heparin-binding epidermal growth factor and transforming growth factor-beta were not altered by infection with any strain. No strain altered MHC class II expression. MHC class I expression was increased with one of the two clinical strains (Clin 1, P=0.0006) and decreased by AD-169 (P=0.0016). Clin 2 and Towne had no effect on MHC class I expression. CONCLUSIONS: These data demonstrate that the genetic heterogeneity of CMV is associated with differences in transplant-relevant biologic activity even among clinical isolates. The relationship between CMV and chronic rejection may be difficult to determine given the heterogeneous nature of this complex virus.
Assuntos
Infecções por Citomegalovirus/patologia , Citomegalovirus/genética , Citomegalovirus/patogenicidade , Endotélio Vascular/fisiologia , Endotélio Vascular/virologia , Substâncias de Crescimento/genética , Transplante de Coração/patologia , Antígenos Virais/genética , Aorta , Células Cultivadas , Citomegalovirus/isolamento & purificação , Infecções por Citomegalovirus/etiologia , Primers do DNA , Fator 2 de Crescimento de Fibroblastos/genética , Variação Genética , Humanos , Fator de Crescimento Derivado de Plaquetas/genética , Reação em Cadeia da Polimerase , Complicações Pós-Operatórias/virologia , RNA Mensageiro/genética , Somatomedinas/genética , Especificidade da Espécie , Fator de Crescimento Transformador alfa/genética , Transplante HomólogoAssuntos
Transplante de Coração/estatística & dados numéricos , Transplante de Pulmão/estatística & dados numéricos , Análise Atuarial , Adolescente , Causas de Morte , Criança , Pré-Escolar , Transplante de Coração/mortalidade , Transplante de Coração-Pulmão/estatística & dados numéricos , Humanos , Terapia de Imunossupressão , Lactente , Transplante de Pulmão/mortalidade , Complicações Pós-Operatórias , Sistema de RegistrosRESUMO
The most common cause of death and retransplantation after heart transplantation is a rapidly progressive, obliterative vascular disease involving the coronary arteries, termed cardiac allograft vasculopathy (CAV). Most believe that this is a form of chronic rejection. Several clinical series have suggested an association between cytomegalovirus and CAV. Rat cytomegalovirus enhances the development of CAV in rat heterotopic heart or aortic transplantation models. The mechanism(s) by which cytomegalovirus might have an impact on the severity of chronic rejection include the augmentation of vascular growth factors, the alteration in the alloimmune response directly or the alteration of cytokines and cell adhesion molecules, enhancing cellular and humoral interactions. We previously reported that the infection of smooth muscle cells by cytomegalovirus resulted in the alteration of major histocompatibility complex class I molecules on the smooth muscle cell surface. In a subsequent report we demonstrated that a sublethal inoculum of cytomegalovirus produced no cytopathology in smooth muscle cells yet had the same viral burden as fibroblasts, which demonstrated cytopathology. The identical effects on major histocompatibility complex class I were observed in smooth muscle cells, and cytokine gene transcription was altered, favoring a proinflammatory milieu. These and most in vitro studies are carried out with the use of traditional laboratory strains of cytomegalovirus. We have subsequently demonstrated major genotypic differences between laboratory and clinical strains of cytomegalovirus that are associated in differences in biological activity in vitro. These include differences in tropism for vascular cells, differences in cell surface antigen expression, and differences in mesenchymal growth factor gene expression. All of these may have important implications with regard to associating cytomegalovirus with CAV.
Assuntos
Doença das Coronárias/virologia , Infecções por Citomegalovirus/complicações , Citomegalovirus/patogenicidade , Transplante de Coração/efeitos adversos , Animais , Células Cultivadas , Estudos de Coortes , Citomegalovirus/genética , Infecções por Citomegalovirus/virologia , Efeito Citopatogênico Viral , Endotélio Vascular/metabolismo , Endotélio Vascular/virologia , Rejeição de Enxerto/virologia , Antígenos de Histocompatibilidade Classe I/biossíntese , Humanos , Músculo Liso Vascular/metabolismo , Músculo Liso Vascular/virologia , RatosAssuntos
Transplante de Coração/estatística & dados numéricos , Transplante de Pulmão/estatística & dados numéricos , Sistema de Registros/estatística & dados numéricos , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Transplante de Coração/mortalidade , Transplante de Coração/tendências , Transplante de Coração-Pulmão/mortalidade , Transplante de Coração-Pulmão/estatística & dados numéricos , Transplante de Coração-Pulmão/tendências , Humanos , Lactente , Cooperação Internacional , Transplante de Pulmão/mortalidade , Transplante de Pulmão/tendências , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Sociedades Médicas , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Increased graft ischemic time and donor age are risk factors for early death after heart transplantation, but the effect of these variables on survival after lung transplantation has not been determined in a large, multinational study. METHODS: All recipients of cadaveric lung transplantations performed between October 1, 1987 and June 30, 1997 which were reported to the United Network for Organ Sharing/International Society for Heart and Lung Transplantation (UNOS/ISHLT) Registry were analyzed. Patient survival rates were estimated using Kaplan-Meier methods. Multivariate logistic regression was used to determine the impact of donor and recipient characteristics on patient survival after transplantation. To examine whether the impact of donor age varied with ischemic time, interactions between the 2 terms were examined in a separate multivariate logistic regression model. RESULTS: Kaplan-Meier survival did not differ according to the total lung graft ischemia time, but recipient survival was significantly adversely affected by young (-10 years) or old (-51 years) donor age (p = 0.01). On multivariate analysis, neither donor age nor lung graft ischemic time per se were independent predictors of early survival after transplantation, except if quadratic terms of these variables were included in the model. The interaction between donor age and graft ischemia time, however, predicted 1 year mortality after lung transplantation (p = 0.005), especially if donor age was greater than 55 years and ischemic time was greater than 6 to 7 hours. CONCLUSIONS: Graft ischemia time alone is not a risk factor for early death after lung transplantation. Very young or old donor age was associated with decreased early survival, whereas the interaction between donor age and ischemic time was a significant predictor of 1 year mortality after transplantation. Cautious expansion of donor acceptance criteria (especially as regards ischemic time) is advisable, given the critical shortage of donor lung grafts.
Assuntos
Isquemia/mortalidade , Transplante de Pulmão/mortalidade , Pulmão/irrigação sanguínea , Doadores de Tecidos , Adolescente , Adulto , Fatores Etários , Criança , Seguimentos , Humanos , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Taxa de Sobrevida , Fatores de TempoRESUMO
BACKGROUND: Current immunosuppression strategies involve inhibition of T cell activation and/or lymphocyte proliferation. During T cell cycle progression/activation, the expression of cyclins and cyclin dependent kinases is increased. In this study, we examined whether cyclosporine A (CsA) suppresses the cell cycle progression through the induction of the cell cycle inhibitor p21. Because CsA induces the expression of transforming growth factor (TGF)-beta, and TGF-beta induces p21 expression, we also determined whether CsA's induction of p21 is dependent on or independent of TGF-beta. METHOD: Using reverse transcription assisted polymerase chain reaction and western blot analysis, we studied the induction of p21 mRNA and protein in human T cells and A-549 cells (human lung adenocarcinoma cells) by CsA. The stimulation of p21 promoter activity was studied by luciferase assay using p21-luc, chimeric plasmid DNA containing a p21 promoter segment, and luciferase reporter gene. The dependence of CsA's induction of p21 was studied using anti-TGF-beta antibody and TGF-beta altered A-549 cells. RESULTS: CsA induced p21 mRNA protein expression and stimulated its promoter activity in lymphoid (T cells) and nonlymphoid (human lung adenocarcinoma, A-549 cells).CsA's induction of p21 was inhibited both by a neutralizing anti-TGF-beta antibody and in TGF-beta-altered A-549 cells, consistent with its effects on p21 requiring TGF-beta. CONCLUSION: These data support the hypothesis that at least one component of CsA's antiproliferative effects may occur through the induction of p21 and that this induction is dependent on TGF-beta. Should p21 induction be a viable immunosuppressive strategy, inducing this molecule independent from the fibrogenic cytokine TGF-beta might reduce the toxicity associated with current immunosuppression.